Why Is ANF Stock Soaring Before The Bell Today?

Published : Nov 25, 2025, 07:00 PM IST
https://stocktwits.com/news-articles/markets/equity/why-anf-stock-is-soaring-before-the-bell-today/cL520AyREXv

Synopsis

Abercrombie now expects net sales to grow in the range of 6% to 7% for fiscal year 2025, compared with the prior forecast of 5% to 7% rise.

Abercrombie & Fitch (ANF) shares jumped nearly 19% in premarket trading on Tuesday after the apparel maker raised the lower end of its annual net sales and profit forecasts heading into the holiday season and betting on growing demand for its namesake brand as well as Hollister’s products.

“Hollister brands grew 16% on a strong finish to back-to-school and fall seasonal transition,” CEO Fran Horowitz said, adding that Abercrombie brands made sequential progress in line with the company’s expectations.

“We are tightly managing inventory as we aim for fourth quarter brand net sales to be approximately flat to last year’s record,” Horowitz said.

Abercrombie now expects net sales to grow in the range of 6% to 7% for fiscal year 2025, compared with the prior forecast of 5% to 7% rise. The company sees annual earnings per share between $10.20 and $10.50, compared to the $10.00 to $10.50 previously estimated.

Get updates to this developing story directly on Stocktwits.<

For updates and corrections, email newsroom[at]stocktwits[dot]com.<

PREV

Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.

Recommended Stories

Peter Schiff Says Investors Have Accepted Gold's Rally Is 'Here To Stay' As Silver Prices Soar To A Fresh High
This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling